Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Activmed Practices and Research LLC

Neither a doctor nor a teaching hospital

Research payments

$3,515,683

395 payments

Through program year 2025, Activmed Practices and Research LLC is reported as receiving $3,515,683 in research payments, across 395 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $890,378 133
2024 Research $644,764 149
2023 Research $809,999 70
2022 Research $593,465 22
2021 Research $577,077 21

Breakdown

Who paid Research payments · program years 2021–2025
  1. Eli Lilly and Company $2,106,599 77 payments
  2. Novavax Inc $282,076 51 payments
  3. Seqirus USA Inc $244,362 81 payments
  4. Sanofi Pasteur Inc. $240,370 11 payments
  5. Currax Pharmaceuticals LLC $110,974 40 payments
  6. Ucb SA $105,876 7 payments
  7. Amgen Inc. $99,830 8 payments
  8. GlaxoSmithKline, LLC. $93,296 43 payments
  9. ITI, Inc. $55,373 14 payments
  10. Janssen Research & Development, LLC $51,082 9 payments
Studies the money was for Research payments · program years 2021–2025
  1. A Randomized, Double-Blinded Study to Evaluate the Efficacy and Safety of Mevidalen in Patients With Alzheimer's Disease $310,820 3 payments
  2. A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines $282,076 51 payments
  3. A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age $238,914 77 payments
  4. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $230,579 2 payments
  5. A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older $230,536 9 payments
  6. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $219,541 4 payments
  7. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-4) $213,284 2 payments
  8. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $203,652 5 payments
  9. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $150,991 2 payments
  10. A Multicenter, Open-Label Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis $93,768 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record